Gilead Sciences (NASDAQ:GILD) Price Target Raised to $90.00 at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD) had its target price upped by equities research analysts at Royal Bank of Canada from $84.00 to $90.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential downside of 15.06% from the stock’s current price.

Several other research firms have also commented on GILD. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Morgan Stanley lifted their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Citigroup began coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.33.

Gilead Sciences Trading Up 2.6 %

GILD opened at $105.96 on Wednesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company’s 50 day simple moving average is $93.38 and its two-hundred day simple moving average is $87.24. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $106.43. The firm has a market capitalization of $132.05 billion, a price-to-earnings ratio of 1,177.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Analysts expect that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 710,500 shares of company stock worth $67,684,956. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nicolet Advisory Services LLC lifted its position in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 100 shares during the last quarter. Avior Wealth Management LLC raised its holdings in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares during the last quarter. Southland Equity Partners LLC raised its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 110 shares during the last quarter. Concord Asset Management LLC VA raised its holdings in shares of Gilead Sciences by 3.8% in the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares during the last quarter. Finally, Berkshire Bank raised its holdings in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 111 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.